CLINICAL TRIALS PROFILE FOR LUPRON

505(b)(2) Clinical Trials for LUPRON

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00626431 ↗	A Study of Leuprolide to Treat Prostate Cancer	Completed	Abbott	Phase 3	2008-02-01	To assess the efficacy and safety of 2 new formulations of leuprolide acetate 45 mg 6-month depot, Formulation A or Formulation B, for the treatment of patients with prostate cancer. A formulation will be deemed successful if the percentage of subjects with suppression of testosterone to

All Clinical Trials for LUPRON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001181 ↗	Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2	1982-10-01	The normal changes of puberty, such as breast enlargement, pubic hair and menstrual periods, usually begin between the ages of 9 and 15 in response to hormones produced in the body. Some children's bodies produce these hormones before the normal age and start puberty too early. This condition is known as precocious puberty. The hormones responsible for the onset of puberty come from the pituitary gland and the ovaries. The hormones from the pituitary gland act on the ovaries to produce different hormones that cause the breasts to grow, pubic hair to develop, and menstruation. Many children with precocious puberty can be treated with a medication known as lutenizing hormone-releasing hormone analog (Lupron, Histerelin, Deslorelin). This drug is made in a laboratory and is designed to act like the natural hormone LHRH, which is made in the pituitary gland. The drug causes the pituitary gland to decrease the amount of hormones it is releasing and thereby decrease the amount of hormones released by the ovaries. However, some girls already have low levels of pituitary hormones and yet their ovaries still produce hormones. Researchers do not believe that LHRH analog therapy will work for these children. Testolactone is a drug that acts directly on the ovary. It works by preventing the last step of estrogen production in the ovary. The goal of this treatment is to stop estrogen production and delay the onset of puberty until the normal age. Researchers will give patients with LHRHa resistant precocious puberty Testolactone for six months. If the initial treatment is successful and patients do not experience very bad side effects, they will continue to receive the medication until puberty is desired. Throughout the therapy patients will receive frequent monitoring of their general state of health, hormone levels, and medication levels.
NCT00001259 ↗	A Treatment Study for Premenstrual Syndrome (PMS)	Completed	National Institute of Mental Health (NIMH)	Phase 1	1992-08-11	This study examines the effects of estrogen and progesterone on mood, the stress response, and brain function and behavior in women with premenstrual syndrome. Previously this study has demonstrated leuprolide acetate (Lupron (Registered Trademark)) to be an effective treatment for PMS. The current purpose of this study is to evaluate how low levels of estrogen and progesterone (that occur during treatment with leuprolide acetate) compare to menstrual cycle levels of estrogen and progesterone (given during individual months of hormone add-back) on a variety of physiologic measures (brain imaging, stress testing, etc.) in women with PMS. PMS is a condition characterized by changes in mood and behavior that occur during the second phase of the normal menstrual cycle (luteal phase). This study will investigate possible hormonal causes of PMS by temporarily stopping the menstrual cycle with leuprolide acetate and then giving, in sequence, the menstrual cycle hormones progesterone and estrogen. The results of these hormonal studies will be compared between women with PMS and healthy volunteers without PMS (see also protocol 92-M-0174). At study entry, participants will undergo a physical examination. Blood, urine, and pregnancy tests will be performed. Cognitive functioning and stress response will be evaluated during the study along with brain imaging and genetic studies.
NCT00001322 ↗	The Effects of Reproductive Hormones on Mood and Behavior	Completed	National Institute of Mental Health (NIMH)	N/A	1994-06-09	This study evaluates the effects of estrogen and progesterone on mood, the stress response, and brain function in healthy women. The purpose of this study is to evaluate how low levels of estrogen and progesterone (that occur during treatment with leuprolide acetate) compare to menstrual cycle levels of estrogen and progesterone (given during individual months of hormone add-back) on a variety of physiologic measures (brain imaging, stress testing, etc.) in healthy volunteer women without PMS. This study will investigate effects of reproductive hormones by temporarily stopping the menstrual cycle with leuprolide acetate and then giving, in sequence, the menstrual cycle hormones progesterone and estrogen. Tests (such as brain imaging or stress testing, etc.) will be performed during the different hormonal conditions (low estrogen and progesterone, progesterone add-back, estrogen add-back). The results of these studies will be compared between women without PMS and women with PMS (see also protocol 90-M-0088). At study entry, participants will undergo a physical examination. Blood, urine, and pregnancy tests will be performed. Cognitive functioning and stress response will be evaluated during the study along with brain imaging and genetic studies.
NCT00001481 ↗	The Role of Hormones in Postpartum Mood Disorders	Recruiting	National Institute of Mental Health (NIMH)	Phase 2	1996-04-26	Determine whether postpartum depression is triggered by the abrupt withdrawal of estrogen and progesterone. The appearance of mood and behavioral symptoms during pregnancy and the postpartum period has been extensively reported. While there has been much speculation about possible biologically based etiologies for postpartum disorders (PPD), none has ever been confirmed. Preliminary results from two related studies (protocols 90-M-0088, 92-M-0174) provide evidence that women with menstrual cycle related mood disorder, but not controls, experience mood disturbances during exogenous replacement of physiologic levels of gonadal steroids. The present protocol is designed to create a "scaled-down" hormonal milieu of pregnancy and the puerperium in order to determine whether women who have had a previous episode of postpartum major effective episode will experience differential mood and behavioral effects compared with controls and to determine whether it is the abrupt withdrawal of gonadal steroids or the prolonged exposure to gonadal steroids that is associated with mood symptoms. Supraphysiologic plasma levels of gonadal steroids will be established, maintained, and then rapidly reduced, simulating the hormonal events that occur during pregnancy and parturition. This will be accomplished by administering estradiol and progesterone to women who are pretreated with a gonadotropin releasing hormone (GnRH) agonist (Lupron). After eight weeks, administration of gonadal steroids will be stopped in one group of patients and controls, and a sudden decline in the plasma hormone levels will be precipitated. Another group will be maintained on supraphysiologic levels of estrogen and progesterone for an additional month. Outcome measures will include mood, behavioral and hormonal parameters (a separate protocol done in collaboration with NICHD).
NCT00002597 ↗	Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1994-10-01	RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, goserelin, and leuprolide may fight prostate cancer by reducing the production of androgens. It is not yet known which regimen of antiandrogen therapy is most effective for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy with or without antiandrogen therapy in treating patients who have stage I or stage II prostate cancer.
NCT00002597 ↗	Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer	Completed	Radiation Therapy Oncology Group	Phase 3	1994-10-01	RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, goserelin, and leuprolide may fight prostate cancer by reducing the production of androgens. It is not yet known which regimen of antiandrogen therapy is most effective for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy with or without antiandrogen therapy in treating patients who have stage I or stage II prostate cancer.

Clinical Trial Conditions for LUPRON

Condition Name

Condition Name for LUPRON
Intervention	Trials
Prostate Cancer	45
Prostate Adenocarcinoma	11
Infertility	7
Stage IV Prostate Cancer	6

Condition MeSH

Condition MeSH for LUPRON
Intervention	Trials
Prostatic Neoplasms	73
Adenocarcinoma	19
Infertility	7
Syndrome	6

Clinical Trial Locations for LUPRON

Trials by Country

Trials by Country for LUPRON
Location	Trials
United States	633
Canada	39
United Kingdom	14
Germany	9
Brazil	7

Trials by US State

Trials by US State for LUPRON
Location	Trials
California	34
Texas	31
Maryland	30
New York	28
Colorado	24

Clinical Trial Progress for LUPRON

Clinical Trial Phase

Clinical Trial Phase for LUPRON
Clinical Trial Phase	Trials
PHASE2	2
Phase 4	15
Phase 3	25

Clinical Trial Status

Clinical Trial Status for LUPRON
Clinical Trial Phase	Trials
Completed	62
Recruiting	27
Terminated	15

Clinical Trial Sponsors for LUPRON

Sponsor Name

Sponsor Name for LUPRON
Sponsor	Trials
National Cancer Institute (NCI)	28
M.D. Anderson Cancer Center	11
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	10

Sponsor Type

Sponsor Type for LUPRON
Sponsor	Trials
Other	150
Industry	64
NIH	53

Lupron (Leuprolide) Clinical Trials, Market Analysis, Patent Status and Sales Projection

Last updated: August 1, 2026

Lupron, the branded leuprolide acetate depot injection, remains a major gonadotropin-releasing hormone (GnRH) agonist in prostate cancer, endometriosis, uterine fibroids and central precocious puberty. Its clinical role is established, but market growth is constrained by oral GnRH antagonists, competing injectable GnRH agents, biosimilar-style peptide competition and long-term pricing pressure. The strongest remaining commercial positions are pediatric endocrinology and patients requiring established depot administration.

What is Lupron and who markets it?

Lupron is leuprolide acetate, a synthetic GnRH agonist that initially increases luteinizing hormone and follicle-stimulating hormone before causing pituitary GnRH-receptor downregulation. The resulting suppression of testosterone or estrogen supports treatment across several hormone-dependent diseases.

Product	Primary indications	Typical administration	Commercial position
Lupron Depot	Advanced prostate cancer	Monthly, three-month, four-month or six-month depot, depending on presentation	Mature oncology product
Lupron Depot-PED	Central precocious puberty	Monthly or three-month depot	Durable pediatric niche
Lupron Depot 3.75 mg	Endometriosis and uterine fibroids	Monthly depot	Competes with newer oral therapies
Leuprolide generics and alternatives	Prostate cancer and endocrine suppression	Depot injection or implant	Increasing price pressure

AbbVie markets Lupron in the United States after acquiring the product through its predecessor Abbott Laboratories. Takeda has also had historical commercial involvement in Lupron-related rights outside the United States. Current regional commercialization should be verified by country because ownership and distribution arrangements differ.

Lupron is not a monoclonal antibody. Biosimilar substitution rules generally do not apply. Competition instead comes from generic or follow-on leuprolide products, alternative depot GnRH agonists, GnRH antagonists and different drug-delivery systems.

What clinical trials have affected Lupron’s competitive position?

Lupron has a large historical evidence base rather than a new pivotal-trial growth story. Recent clinical development has focused on comparative cardiovascular outcomes, oral alternatives and disease-specific treatment strategies.

How does Lupron compare with relugolix in prostate cancer?

The HERO phase 3 trial compared oral relugolix with leuprolide in men with advanced prostate cancer. Relugolix achieved sustained testosterone suppression and showed fewer major adverse cardiovascular events than leuprolide in the reported safety analysis. The study was not designed primarily as a cardiovascular superiority trial, but its results increased physician and investor attention toward oral GnRH antagonism (Shore et al., 2020).

The commercial implication is direct:

Attribute	Lupron	Relugolix
Mechanism	GnRH agonist	GnRH antagonist
Testosterone flare	Yes, unless covered with an antiandrogen	No initial flare
Administration	Depot injection	Daily oral tablet
Adherence risk	Lower dosing frequency	Daily adherence required
Cardiovascular discussion	Class concern for androgen-deprivation therapy	Favorable signal in HERO
Reversibility	Slower after depot dosing	Faster after discontinuation
Commercial risk	Administration infrastructure and established use	Oral convenience and no flare

Lupron remains relevant for patients who prefer infrequent dosing, have difficulty taking daily medication or are treated within established oncology injection pathways. Relugolix is more competitive when rapid testosterone recovery, avoidance of flare or cardiovascular risk management has priority.

What did the PRONOUNCE trial show?

PRONOUNCE directly compared the GnRH antagonist degarelix with leuprolide in men with prostate cancer and established atherosclerotic cardiovascular disease. The trial stopped early because of slow enrollment and low event rates. It did not demonstrate a statistically significant difference in major adverse cardiovascular events between the two treatments (Lopes et al., 2021).

PRONOUNCE reduced the certainty of broad claims that GnRH antagonists consistently lower cardiovascular risk versus leuprolide. The trial did not remove the competitive advantage of avoiding testosterone flare, but it weakened the case for treating cardiovascular benefit as a settled class distinction.

What is the clinical-trial outlook for Lupron in endometriosis and fibroids?

Lupron is unlikely to generate major label expansion in these indications. Development has shifted toward oral GnRH antagonists, particularly elagolix and relugolix combinations that provide estrogen suppression with add-back therapy.

The main clinical-development themes are:

• Oral GnRH antagonists for endometriosis-associated pain.
• Oral GnRH antagonists for heavy menstrual bleeding caused by fibroids.
• Add-back therapy to reduce bone mineral density loss and vasomotor symptoms.
• Longer-term safety and treatment-duration studies.
• Comparative studies of depot injections versus oral hormonal suppression.

These developments place Lupron under greater pressure in gynecology than in pediatric endocrinology.

What is the FDA regulatory status of Lupron?

Lupron has longstanding FDA approvals across multiple formulations and indications. The product’s regulatory value comes from established safety, dosing history and physician familiarity rather than recent FDA innovation.

The principal regulatory issues are:

1. Testosterone flare during initiation in prostate cancer.
2. Bone mineral density loss with prolonged sex-hormone suppression.
3. Hot flashes and other hypoestrogenic or hypoandrogenic effects.
4. Injection-site reactions and depot administration complications.
5. Need for careful dosing by age, indication and formulation.
6. Pediatric monitoring of growth, puberty progression and bone maturation.

Lupron Depot-PED remains important because central precocious puberty requires reliable suppression over time, and pediatric endocrinologists often favor products with extensive long-term clinical experience.

What patents protect Lupron and when does exclusivity end?

Lupron’s original composition-of-matter and formulation patents have expired. The product is a mature small-molecule peptide depot with no meaningful remaining basic patent exclusivity in the United States.

The commercial barriers are more likely to involve:

• Depot microsphere manufacturing.
• Peptide loading and release-control processes.
• Sterility and stability requirements.
• Device and reconstitution systems.
• Product-specific regulatory requirements.
• Formulation know-how and manufacturing scale.

The FDA Orange Book should be reviewed by specific NDA and strength because listed patents can vary by presentation and may include method-of-use or delivery-system claims. Lupron’s core exclusivity does not resemble a modern biologic franchise protected by an extensive sequence patent estate.

How strong is the Lupron patent estate?

The patent estate is commercially moderate to weak for the active ingredient and stronger for execution. A competitor that can reproduce the depot release profile, sterility specifications, particle characteristics and clinical performance can erode pricing even without duplicating every historical manufacturing step.

The principal risk is therefore regulatory and technical replication, not a long-dated compound patent.

Which companies challenge Lupron?

Lupron competes with products across four groups.

Competitor	Company	Product type	Main competitive issue
Eligard	Tolmar	Leuprolide acetate polymer depot	Same active ingredient; differentiated delivery system
Fensolvi	Tolmar	Six-month leuprolide depot	Pediatric and long-interval dosing competition
Firmagon	Ferring	Degarelix injection	No testosterone flare
Orgovyx	Myovant, now part of Sumitomo Pharma	Oral relugolix	Oral dosing and rapid reversibility
Camcevi	Accord BioPharma	Six-month leuprolide depot	Direct long-acting leuprolide competition
Trelstar	Veru	Triptorelin depot	Alternative GnRH agonist
Vantas	Endo	Histrelin implant	Long-duration implant option

Fensolvi and Camcevi are particularly relevant because they compete for the same clinical logic: long-duration leuprolide suppression with fewer annual administrations.

What is the Orange Book and litigation status of Lupron?

Lupron does not have the type of active, high-profile Paragraph IV litigation profile associated with newer blockbuster products. The major U.S. market risk is gradual substitution, contracting and competition from alternative depot products rather than a single binary patent-case outcome.

Key legal points include:

• Paragraph IV filings may target formulation or delivery patents rather than leuprolide itself.
• Depot products can face abbreviated applications or other product-specific regulatory pathways.
• A competing product may obtain approval while remaining subject to commercial launch restrictions from patent litigation.
• Method-of-use patents are less likely to prevent broad entry where the active ingredient and indications are mature.
• Device, reconstitution and administration patents can affect particular presentations without protecting the entire Lupron franchise.

No broad, long-dated patent barrier should be assumed for Lupron without a current review of each relevant Orange Book listing, FDA approval package and district-court docket.

What is the Lupron market size and revenue exposure?

AbbVie does not report Lupron as a separately disclosed major product line in its standard public financial reporting. Standalone revenue therefore cannot be inferred reliably from company filings. Lupron revenue is embedded within broader pharmaceutical reporting.

The addressable market includes:

• Androgen-deprivation therapy for prostate cancer.
• Pediatric treatment of central precocious puberty.
• Endometriosis-associated pain.
• Uterine fibroid symptoms.
• Fertility and assisted-reproduction protocols, where leuprolide is used off-label or under specialized practice protocols.

The commercial center of gravity is prostate cancer, but the pediatric franchise has stronger defensibility because treatment decisions emphasize long-term evidence, dosing reliability and specialist familiarity.

What is the Lupron market projection through 2030?

A reasonable base-case outlook is a low-single-digit annual decline in branded Lupron revenue through 2030, offset partly by demand growth in prostate cancer and continued pediatric use.

Scenario	2024-2030 branded Lupron trend	Main drivers
Bear case	-8% to -12% CAGR	Rapid oral-antagonist adoption, contracting pressure and depot competition
Base case	-3% to -6% CAGR	Stable prostate-cancer demand, pediatric resilience and gradual substitution
Upside case	0% to +2% CAGR	Higher prostate-cancer prevalence, strong six-month depot uptake and limited oral conversion

The broader GnRH agonist market can remain stable or grow modestly while Lupron declines. Market expansion from cancer prevalence and longer treatment duration does not guarantee branded revenue growth because price erosion and product switching can absorb volume gains.

What is the generic launch risk?

Generic and follow-on launch risk is highest in mature adult indications. The risk is lower in pediatric endocrinology because physicians and payers may prioritize clinical continuity, specialist experience and reliable suppression.

A likely launch sequence is:

1. Price competition in standard monthly and three-month adult depot presentations.
2. Contracting pressure in oncology practices and hospital systems.
3. Increased switching to six-month leuprolide products.
4. Selective adoption of oral GnRH antagonists in cardiovascular-risk patients.
5. Continued retention of Lupron Depot-PED in specialist pediatric practices.

How does Lupron compare with newer hormonal therapies?

Lupron has the widest historical evidence base and a familiar depot model. Its weaknesses are testosterone flare, delayed reversibility, injection burden and adverse effects from prolonged sex-hormone suppression.

Factor	Lupron	Oral GnRH antagonists	Six-month leuprolide products
Clinical familiarity	Very high	Increasing	High for leuprolide
Flare risk	Present	Absent	Present
Dosing frequency	Monthly to six-month	Daily	Six-month
Manufacturing complexity	High	Lower physical complexity	High
Patent durability	Limited	Typically stronger for newer products	Product-specific
Price pressure	High	Moderate to high	Increasing
Pediatric position	Strong	Limited or indication-specific	Strong where approved

Key Takeaways

• Lupron is a mature leuprolide acetate depot franchise with established FDA approvals.
• Prostate cancer remains the largest commercial indication.
• Central precocious puberty is the most defensible specialty market.
• Relugolix and degarelix challenge Lupron through no-flare treatment, oral dosing or cardiovascular positioning.
• Fensolvi, Eligard and Camcevi create direct leuprolide and depot-delivery competition.
• Core compound patents have expired; manufacturing, formulation and regulatory execution remain the principal barriers.
• Branded Lupron revenue is likely to decline at a low-single-digit to mid-single-digit annual rate through 2030 in the base case.
• The franchise has no single dominant Paragraph IV threat comparable to a still-patent-protected blockbuster.
• Volume growth in prostate cancer is unlikely to offset pricing pressure and therapeutic substitution fully.

FAQs

Is Lupron still patent protected?

The original leuprolide composition and principal historical exclusivity have expired. Remaining protection, where applicable, is more likely to concern specific formulations, delivery systems, manufacturing methods or methods of use.

Is Lupron a biologic with biosimilar competition?

No. Lupron is a peptide drug product, not a monoclonal antibody biologic. Its competitive framework involves generics, follow-on depot products and alternative GnRH therapies rather than formal biosimilar substitution.

Which Lupron competitor has the greatest commercial threat?

Orgovyx presents the clearest mechanism and administration challenge in prostate cancer. Fensolvi and Camcevi pose the most direct product-level threat because they retain leuprolide while competing on dosing interval and delivery.

Does Lupron increase cardiovascular risk?

Androgen-deprivation therapy, including GnRH agonist treatment, carries cardiovascular considerations. The comparative cardiovascular advantage of GnRH antagonists remains clinically relevant but was not definitively established by the prematurely terminated PRONOUNCE trial.

Can Lupron be replaced by a generic injection?

Replacement depends on the formulation, indication, FDA approval, payer policy and physician preference. Depot products are technically more complex than conventional injectable generics because release characteristics, sterility and administration requirements must be reproduced.

References

1. AbbVie Inc. (2024). Annual report 2023.
2. Food and Drug Administration. (2024). Drugs@FDA: Lupron Depot and Lupron Depot-PED prescribing information. U.S. Department of Health and Human Services.
3. Lopes, R. D., Bingham, J. B., Kolls, B. J., et al. (2021). Cardiovascular safety of degarelix versus leuprolide for advanced prostate cancer: The PRONOUNCE randomized trial. Circulation, 144(16), 1295-1307.
4. Shore, N. D., Saad, F., Cookson, M. S., et al. (2020). Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. New England Journal of Medicine, 382, 2187-2196.
5. U.S. Patent and Trademark Office. (2024). Patent Center.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.